PRQR - ProQR Therapeutics N.V.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
7.04
+0.01 (+0.14%)
At close: 4:00PM EDT

6.92 -0.12 (-1.64%)
After hours: 4:14PM EDT

Stock chart is not supported by your current browser
Previous Close7.03
Open7.03
Bid6.94 x 2200
Ask7.10 x 1000
Day's Range6.78 - 7.22
52 Week Range6.73 - 24.00
Volume126,760
Avg. Volume185,306
Market Cap273.945M
Beta (3Y Monthly)-0.37
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.22
Trade prices are not sourced from all markets
  • Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
    Zacks

    Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

    Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.

  • GlobeNewswire

    ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-1123. QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. Fast Track designation is granted by the FDA to drugs in development for serious conditions with the potential to fulfill an unmet medical need.

  • Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
    Zacks

    Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study

    Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.

  • Mallinckrodt Enrolls First Patient in Liver Disease Study
    Zacks

    Mallinckrodt Enrolls First Patient in Liver Disease Study

    Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.

  • GlobeNewswire

    ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a Phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying cause of the vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene.

  • ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of 24.44% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    ProQR Announces Financial Results for the Second Quarter of 2019

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • GlobeNewswire

    European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced today that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA). As of June 2019, less than 30% (54 out of 181) of applications to the PRIME program have been granted access, and only 20% (one out of five) of ophthalmology applications have been granted access. “The EMA’s decision to grant PRIME access to sepofarsen further highlights the need for truly groundbreaking medicines to treat LCA10 patients, especially considering the rigorous selection process of the program.

  • What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?
    Simply Wall St.

    What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?

    Daniel de Boer became the CEO of ProQR Therapeutics N.V. (NASDAQ:PRQR) in 2012. This analysis aims first to contrast...

  • GlobeNewswire

    ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July

    LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • Here’s What Hedge Funds Think About ProQR Therapeutics NV (PRQR)
    Insider Monkey

    Here’s What Hedge Funds Think About ProQR Therapeutics NV (PRQR)

    Insider Monkey finished processing more than 738 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2019. In this article we are going to take a look at smart money sentiment towards ProQR Therapeutics NV (NASDAQ:PRQR). ProQR Therapeutics NV (NASDAQ:PRQR) has seen a decrease […]

  • GlobeNewswire

    ProQR to Present at the JMP Securities Life Sciences Conference

    LEIDEN, the Netherlands and CAMBRIDGE, Mass., June 03, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?
    Simply Wall St.

    Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

  • GlobeNewswire

    ProQR to Present at the RBC Capital Markets Healthcare Conference

    LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation.

  • Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR)
    Insider Monkey

    Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR)

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of -13.89% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    ProQR: 1Q Earnings Snapshot

    On a per-share basis, the Leiden, Netherlands-based company said it had a loss of 41 cents. ProQR shares have fallen 30% since the beginning of the year. The stock has more than doubled in the last 12 ...

  • GlobeNewswire

    ProQR Announces Financial Results for the First Quarter of 2019

    LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • GlobeNewswire

    ProQR to Present at Three Scientific Conferences in April

    LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • GlobeNewswire

    ProQR Announces Annual Meeting of Shareholders

    LEIDEN, Netherlands and CAMBRIDGE, Mass., April 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • GlobeNewswire

    ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

    LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • ProQR Initiates Dosing in Phase II/III Eye Disorder Study
    Zacks

    ProQR Initiates Dosing in Phase II/III Eye Disorder Study

    ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

  • GlobeNewswire

    ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 2/3 ILLUMINATE clinical trial for sepofarsen (formerly named QR-110) in patients with Leber’s Congenital Amaurosis 10 (LCA10). “Inherited retinal degenerations caused by mutations in the CEP290 gene frequently lead to blindness in early childhood. No form of therapy is currently available,” said Dr. Katarina Stingl of the Center for Ophthalmology in Tübingen, Investigator in the ILLUMINATE trial.

  • GlobeNewswire

    ProQR to Present at the H.C. Wainwright Global Life Sciences Conference

    LEIDEN, Netherlands and CAMBRIDGE, Mass., April 01, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • GlobeNewswire

    ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the strategic spin out of the Dystrophic Epidermolysis Bullosa (DEB) activities into the newly formed company, Wings Therapeutics. Wings Therapeutics is formed and financed by EB Research Partnership (EBRP), the largest global non-profit dedicated to treating and curing EB. Wings Therapeutics will be led by interim CEO Mark de Souza, PhD, former CEO of Lotus Tissue Repair and Hal Landy, MD, former medical advisor to Lotus Tissue Repair and CMO of Enobia.